Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients.

Wei KC, Sy C, Wu SY, Chuang TJ, Huang WC, Lai PC.

Sci Rep. 2018 May 29;8(1):8321. doi: 10.1038/s41598-018-26743-4.

2.

The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.

Isidori A, Merli F, Angrilli F, Ferrara F, Alesiani F, Visani G.

Leuk Lymphoma. 2011 Jan;52(1):148-9. doi: 10.3109/10428194.2010.525726. Epub 2010 Nov 11. No abstract available.

PMID:
21067442
3.

Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.

Kim T, Choi SH, Kim SH, Jeong JY, Woo JH, Kim YS, Sung H, Kim MN, Yoon DH, Suh C, Lee SO.

Ann Hematol. 2013 Jan;92(2):231-8. doi: 10.1007/s00277-012-1592-1. Epub 2012 Oct 10.

PMID:
23053189
4.
5.

Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.

Barreto JN, Ice LL, Thompson CA, Tosh PK, Osmon DR, Dierkhising RA, Plevak MF, Limper AH.

Am J Hematol. 2016 Nov;91(11):1113-1117. doi: 10.1002/ajh.24499. Epub 2016 Aug 22.

6.

The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.

Hardak E, Oren I, Dann EJ, Yigla M, Faibish T, Rowe JM, Avivi I.

Acta Haematol. 2012;127(2):110-4. doi: 10.1159/000334113. Epub 2011 Dec 16.

PMID:
22178955
7.

Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.

Haeusler GM, Slavin MA, Seymour JF, Lingaratnam S, Teh BW, Tam CS, Thursky KA, Worth LJ.

Eur J Haematol. 2013 Aug;91(2):157-63. doi: 10.1111/ejh.12135. Epub 2013 Jun 15.

PMID:
23668894
8.

Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.

Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R.

Eur J Haematol. 2008 Mar;80(3):275-6. Epub 2007 Nov 15. No abstract available.

PMID:
18005387
9.

Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.

Hashimoto K, Kobayashi Y, Asakura Y, Mori M, Azuma T, Maruyama D, Kim SW, Watanabe T, Tobinai K.

Leuk Lymphoma. 2010 Oct;51(10):1816-21. doi: 10.3109/10428194.2010.506569.

PMID:
20919860
10.

Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.

Neofytos D, Hirzel C, Boely E, Lecompte T, Khanna N, Mueller NJ, Boggian K, Cusini A, Manuel O, van Delden C; Swiss Transplant Cohort Study.

Transpl Infect Dis. 2018 Dec;20(6):e12984. doi: 10.1111/tid.12984. Epub 2018 Sep 19.

11.

Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.

Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS.

Korean J Intern Med. 2010 Mar;25(1):86-92. doi: 10.3904/kjim.2010.25.1.86. Epub 2010 Feb 26.

12.

Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.

Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson HD, Wolf J, Greene W.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00173-18. doi: 10.1128/AAC.00173-18. Print 2018 Aug.

13.

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.

Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D.

Haematologica. 2007 Jan;92(1):139-40.

14.

High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.

Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS.

Leuk Lymphoma. 2010 May;51(5):797-801. doi: 10.3109/10428191003699860.

PMID:
20367135
15.

Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study.

Lee KY, Huang CH, Tang HJ, Yang CJ, Ko WC, Chen YH, Lee YC, Hung CC.

J Antimicrob Chemother. 2012 Nov;67(11):2749-54. doi: 10.1093/jac/dks283. Epub 2012 Jul 20.

PMID:
22821870
16.

Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.

Huang YS, Yang JJ, Lee NY, Chen GJ, Ko WC, Sun HY, Hung CC.

Expert Rev Anti Infect Ther. 2017 Sep;15(9):873-892. doi: 10.1080/14787210.2017.1364991. Epub 2017 Aug 21. Review.

PMID:
28782390
17.

Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection.

Su YS, Lu JJ, Perng CL, Chang FY.

J Microbiol Immunol Infect. 2008 Dec;41(6):478-82.

PMID:
19255691
18.

Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.

Salzer HJF, Schäfer G, Hoenigl M, Günther G, Hoffmann C, Kalsdorf B, Alanio A, Lange C.

Respiration. 2018;96(1):52-65. doi: 10.1159/000487713. Epub 2018 Apr 10. Review.

19.

Pulmonary co-infections by Pneumocystis jirovecii and Aspergillus fumigatus in non-HIV patients: A report of two cases and literature review.

Markantonatou AM, Ioakimidou A, Arvaniti K, Manou E, Papadopoulos V, Kiriklidou P, Samaras K, Kioumi A, Vyzantiadis TA.

Mycoses. 2017 Oct;60(10):626-633. doi: 10.1111/myc.12642. Epub 2017 Jun 28. Review.

PMID:
28660636
20.

Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.

Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Y, Tamura K.

Leuk Lymphoma. 2009 Nov;50(11):1818-23. doi: 10.3109/10428190903258780.

PMID:
19863173

Supplemental Content

Support Center